Caribou Biosciences, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+89.7% +$2M
$4M
R&D↓-21.8% -$7M
$24M
D&A↓-42.4% -$502K
$682K
Operating Income↑+23.1% +$9M
$-29M
EBITDA↓-42.4% -$502K
$682K
Interest Expense
—
Other Income/Expense
—
Pretax Income
—
Tax Provision
$0
Net Income↑+20.6% +$7M
$-28M
Operating Margin↑+551.6pts
-1337.6%
Net Margin↑+460.3pts
-1253.3%
Effective Tax Rate
—
Deferred Tax Liabilities
$0
ETR (Continuing Operations)↑+0.4pts
0.4%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+8.5pts
0.5%
Operating Lease Cost↓-2.7% -$51K
$2M
Revenue YoY Variation↑+131.4pts
89.7%
Income YoY Variation↑+184.4pts
23.1%
Revenue QoQ Variation↑+76.7pts
79.3%
Income QoQ Variation↑+26.1pts
38.2%